SHORT MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 01:42:25 2024-07-16 pm EDT | ||
| 22.32 EUR | -1.41% |
|
| Current month | -5.38% | ||
| 1 month | -0.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 22.32 | -1.41% |
| 24-07-15 | 22.64 | +1.98% |
| 24-07-12 | 22.2 | -2.84% |
| 24-07-11 | 22.85 | -2.18% |
| 24-07-10 | 23.36 | +0.65% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 01:42 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ9JYE |
| ISIN | DE000VQ9JYE8 |
| Date issued | 2021-07-13 |
| Strike | 3,514 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 14.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.41 € |
|---|---|
| Lowest since issue | 2.95 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,828
DKK
Average target price
2,446
DKK
Spread / Average Target
+33.83%
- Stock Market
- Certificates
- Certificat
